Merck & Co.’s move to discontinue its hospital antibiotic six years into its launch may have been a surprise, but not a huge one. Large pharma has been backing out of antibiotics for the better part of a decade – AstraZeneca, Novartis and J&J have all left the field.
Merck, which once held one of the deepest anti-infective franchises in the industry, now has no antibacterial program in Phase II or beyond. We dig into why small biotechs are likely to inherit the antibiotic pipeline, and why they might not be able to afford to do it.
A Struggling Antibiotic Pipeline
The backdrop for Merck’s retreat is the Access to Medicine Foundation’s 2026 AMR Benchmark, its fourth. This year, it assessed 25 companies: seven large research-based players, ten generics makers and, for the first time, eight small- and mid-sized enterprises.